Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Budigalimab in People Living With HIV-1
NCT04799353Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2021
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of budigalimab in human immunodeficiency virus type 1 infection (HIV-1) (4 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants Experiencing Study Drug-Related Grade 3 or Higher Adverse Events, Number of Participants With Study Drug-Related Immune-Related Adverse Events and 4 more. Started Mar 2021; status: completed.
02
Drugs
budigalimab
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04799353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04799353.